Correction to “Efficacy and Safety of Early-Start Deferiprone in Infants and Young Children With Transfusion-Dependent Beta Thalassemia: Evidence for Iron Shuttling to Transferrin in a Randomized, Double-Blind, Placebo-Controlled, Clinical Trial (START)”

Abstract

M. S. Elalfy, M. Hamdy, A. Adly, et al., “Efficacy and Safety of Early-Start Deferiprone in Infants and Young Children With Transfusion-Dependent Beta Thalassemia: Evidence for Iron Shuttling to Transferrin in a Randomized, Double-Blind, Placebo-Controlled, Clinical Trial (START),” American Journal of Hematology 98, no. 9 (2023): 1415–1424, https://doi.org/10.1002/ajh.27010.

In the acknowledgements and in the Supplemental Figure 1, the paper omits to mention the contribution made by the study sites in Indonesia and the Pediatric Hospital of Cairo. As these sites are not represented in the author's masthead, we would like to remedy this under the provision given in your correction reasons: “Acknowledgements of funder support or non-author contributors have not been included; or declarations related to ethics approval or conflicts of interest need to be added.”

To support this, we have pasted the desired acknowledgement section below and appended the proposed Supplemental Figure 1 (the addition there being the addition of the Study Site table at the bottom).

This correction has been discussed and approved by all authors, contributors and sponsors.

PROPOSED NEW ACKNOWLEDGEMENTS

The authors thank the patients and their families for participation in this study. The authors would also like to acknowledge the contributions of Professor Amal Beshlawy and her team at Pediatric Hospital of Cairo University (Cairo, Egypt) and Prof Pustika Amalia Wahidiyat and her team at Rumah Sakit Umum Pusat National Dr. Cipto Mangunkusumo (Jakarta, Indonesia), who were investigators and study sites. The study was sponsored by Chiesi Global Rare Diseases (formerly ApoPharma Inc.), Boston, MA, USA. Medical writing support was provided by Keith M. Olson, PhD, and Emily K. LaVigne, PhD, of Oxford PharmaGenesis Inc., Newtown, PA, USA, and funded by Chiesi USA Inc.

We apologize for this error.